Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2023-08-23 00:00:00 ET · period of report 2023-08-21 · accession 0000905148-23-000783 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-23 | 2023-08-21 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +494.0K | 2.90M | +21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-21 | A | A | 493,994 | $0.00 | 2,897,696 | D | — | — |